Press Release: Second Genome : Second Genome Presents New Preclinical Data at AACR 2022 Demonstrating that SG-3-06686, a CXCR3 Chemokine Receptor Modulator, Induces Migration of Immune Effector Cells, Inhibits Tumor Growth as Monotherapy and Boosts Anti-Programmed Death Protein-1 (PD-1) Activity
Lead oncology program candidate SG-3-06686 shows potential to become first in class CXCR3 immune activator BRISBANE, Calif., April 8, 2022 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and...
Read full article »
Second Genome is a clinical-stage pharmaceutical company that focuses on developing microbiome-based therapeutics for the treatment of chronical diseases and illness.
Read more